MedTrace Logo

Postoperative Recovery in Elderly Patients Undergoing Hip Hemi-arthroplasty

NCT01934049 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2013-09-10

No results posted yet for this study

Summary

Hip fractures incidence grows rapidly with the aging of the population. After indicated surgical treatment, hip fracture patients experience high rates of postoperative complications, postoperative delirium (PD), postoperative cognitive dysfunction (POCD), leading to poor postoperative recovery during hospitalization, which can cause disability, distress for both patients and their families, are associated with other medical complications and account for significant additional health care costs. We currently use dexmedetomidine in elderly patients with hip fractures undergoing hip hemi-arthroplasty in order to improve postoperative recovery and prevent and treating PD and POCD.

Dexmedetomidine is a drug used for sedation in critically ill patients that provides some pain relief and controls the bodies response to stress. The sedation produced by dexmedetomidine appears more similar to natural sleep than any other drug used for anesthesia and postoperative sedation. Data suggesting that dexmedetomidine can prevent delirium following cardiac surgery and the developing understanding of the causes of PD and POCD suggest that dexmedetomidine will be particularly effective.

Conditions

  • Femoral Neck Fractures
  • Postoperative Complications
  • Inflammatory Response
  • Postoperative Delirium
  • Postoperative Cognitive Dysfunction

Interventions

PROCEDURE

hip arthroplasty

Every patient with femoral neck fractures must undergo hip hemi-arthroplasty.

DRUG

Total Intravenous Anesthesia and Peripheral nerve blocks

Every patient receives Peripheral nerve blocks and Total Intravenous Anesthesia with propofol

Sponsors & Collaborators

  • Chinese PLA General Hospital

    lead OTHER

Principal Investigators

  • zhang hong, ph.d · Anesthesia and Operation Center, Chinese People's Liberation Army General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2014-02-28
Completion
2014-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01934049 on ClinicalTrials.gov